Anzeige
Mehr »
Login
Donnerstag, 24.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Jetzt knallt's an der Börse! Diese Aktie hat das Zeug zum Überflieger!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von Pharmaceutical Business Review

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
13:27NICE issues final guidance endorsing Pharming's APDS therapy
MiEnsem Therapeutics' application for ETX-636 secures FDA clearance
DiViatris files applications in Japan for approval of Effexor to treat GAD
MoUS FDA clears Calidi's CLD-201 for clinical development in solid tumours
17.04.Glycomine secures $115m funding for Phase IIb trial of rare disease drug
16.04.Norgine agrees to acquire Theravia
15.04.INmune Bio, CGT Catapult to set up manufacturing for cell therapy platforms
14.04.Nona Biosciences and Atossa team up to discover breast cancer therapies
11.04.Imbria secures $57.5m to advance ninerafaxstat through Phase IIb nHCM trial
10.04.Renovaro closes merger transaction with BioSymetrics
09.04.France 2030 funds 4MB's knee osteoarthritis drug trial
08.04.ALX Oncology's ALX2004 gains FDA IND clearance to treat solid tumours
07.04.FDA grants breakthrough therapy status for Amgen's Uplizna to treat IgG4-RD
04.04.FDA clears Epicrispr's application for FSHD treatment
03.04.FDA grants fast track status to Biogen's BIIB080 for Alzheimer's
02.04.EC grants orphan designation for Pharvaris' deucrictibant drug
01.04.Japan's MHLW authorises Regeneron and Sanofi's Dupixent for COPD
28.03.BridgeBio's Beyonttra gains approval in Japan for ATTR-CM treatment
27.03.US FDA approves Exelixis' Cabometyx for advanced neuroendocrine tumours
26.03.US FDA grants orphan drug status to Palatin's obesity treatment PL7737
25.03.NeuroNOS secures funding for autism treatment development
24.03.Duke-NUS and NUS Medicine launch centre for metabolomics research
21.03.FDA approves Novartis' Fabhalta for C3 glomerulopathy treatment
20.03.Porton Advanced and Eureka to expedite T-cell therapy development
19.03.Delpharm plans $140m investment to upgrade Boucherville facility in Canada